Clinical activity of crizotinib in lung adenocarcinoma harboring a HLA_A-ROS1 rearrangement: A case report

被引：0
|
作者：
Kinoshita, Ryosuke [1 ]
Nakao, Makoto [1 ,2 ]
Kiyotoshi, Hiroko [1 ]
Hayashi, Syuntaro [1 ]
Sugihara, Masahiro [1 ]
Hirata, Yuya [1 ]
Kuriyama, Mamiko [1 ]
Takeda, Norihisa [1 ]
Muramatsu, Hideki [1 ]
机构：
[1] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, Yatomi, Aichi 4988502, Japan
[2] Kainan Hosp Aichi Prefectural Welf Federat Agr Coo, Dept Resp Med, 396 Minamihonndenn,Maegasu Cho, Yatomi, Aichi 4988502, Japan
来源：
ONCOLOGY LETTERS | 2023年 / 26卷 / 06期
关键词：
crizotinib; HLA_A-ROS1; Lung adenocarcinoma; multigene panel assay;
D O I：
10.3892/ol.2023.14102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The benefits of crizotinib therapy in patients with tyrosine receptor kinase ROS proto-oncogene 1 (ROS1)-rearranged non-small cell lung cancer (NSCLC) have been demonstrated. The present study reports a 47-year-old woman with lung adenocarcinoma harboring a rare HLA_A-ROS1 rearrangement with clinical response to crizotinib. To the best of our knowledge there have been no reports of HLA_A-ROS1-rearranged lung cancer regarding clinical course and the efficacy of treatment with crizotinib. A good response to crizotinib therapy in the present case could be a reference for the treatment and prognosis of ROS1-rearranged NSCLC with the same fusion partner. The current report will remind oncologists and pulmonologists to consider the importance of accurate multigene panel assays for detecting driver oncogenes in treating patients with NSCLC.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Elevation of tumor mutation burden in ROS1-fusion lung adenocarcinoma resistant to crizotinib A case report
    Yang, Tao
    Xu, Rui
    Yan, Bing
    Li, Fang
    Liu, Hui
    MEDICINE, 2018, 97 (52)
  • [22] ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
    Xu, Shuguang
    Wang, Wenxian
    Xu, Chunwei
    Li, Xingliang
    Ye, Junhui
    Zhu, Youcai
    Ge, Ting
    BMC CANCER, 2019, 19 (01)
  • [23] ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib
    Shuguang Xu
    Wenxian Wang
    Chunwei Xu
    Xingliang Li
    Junhui Ye
    Youcai Zhu
    Ting Ge
    BMC Cancer, 19
  • [24] Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report
    Dong, Liang
    Xia, Jingwen
    Zhang, Jing
    Zhang, Yuanyuan
    Zhu, Ning
    Zhang, Peng
    Zhang, Youzhi
    Zhang, Xiujuan
    Li, Shengqing
    BMC PULMONARY MEDICINE, 2018, 18
  • [25] Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report
    Liang Dong
    Jingwen Xia
    Jing Zhang
    Yuanyuan Zhang
    Ning Zhu
    Peng Zhang
    Youzhi Zhang
    Xiujuan Zhang
    Shengqing Li
    BMC Pulmonary Medicine, 18
  • [26] Crizotinib, an Effective Agent in ROS1-Rearranged Adenocarcinoma of Lungs: A Case Report
    Joshua, Julie Mariam
    Salima, K. D.
    Pavithran, K.
    Vijayan, Meenu
    CLINICAL MEDICINE INSIGHTS-CASE REPORTS, 2018, 11 : 1 - 3
  • [27] Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
    Mazieres, Julien
    Zalcman, Gerard
    Crino, Lucio
    Biondani, Pamela
    Barlesi, Fabrice
    Filleron, Thomas
    Dingemans, Anne-Marie C.
    Lena, Herve
    Monnet, Isabelle
    Rothschild, Sacha I.
    Cappuzzo, Federico
    Besse, Benjamin
    Thiberville, Luc
    Rouviere, Damien
    Dziadziuszko, Rafal
    Smit, Egbert F.
    Wolf, Jurgen
    Spirig, Christian
    Pecuchet, Nicolas
    Leenders, Frauke
    Heuckmann, Johannes M.
    Diebold, Joachim
    Milia, Julie D.
    Thomas, Roman K.
    Gautschi, Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 992 - +
  • [28] Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant
    Zhao, Zheng
    Song, Zhangjun
    Wang, Xuwei
    Sun, Haifeng
    Yang, Xiaomin
    Yuan, Yong
    Yu, Pan
    ONCOTARGETS AND THERAPY, 2017, 10 : 4129 - 4133
  • [29] ROS1 Fusion and MET Amplification Dual Drive Coexistence in Lung Adenocarcinoma and Response to Crizotinib: A Case Report
    Xu, C.
    Wang, W.
    Song, Z.
    Zhang, Q.
    Zhuang, W.
    Chen, Y.
    Chen, G.
    Fang, M.
    Lv, T.
    Song, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1032 - S1032
  • [30] Case Report: Detection of Double ROS1 Translocations, SDC4-ROS1 and ROS1-GK, in a Lung Adenocarcinoma Patient and Response to Crizotinib
    Xu, Long
    Chen, Xiaoxia
    Huo, Hong
    Liu, Yongye
    Yang, Xiaodan
    Gu, Dejian
    Yuan, Mingming
    Zhang, Min
    Chen, Rongrong
    Wang, Jiayin
    Zheng, Zhendong
    FRONTIERS IN MEDICINE, 2021, 8
12345